Doctors use cholinesterase inhibitors and memantine for memory and thinking symptoms, amyloid-clearing infusions to slow early Alzheimer's, and brexpiprazole for agitation. Dementia means a decline in memory, thinking, and daily function caused by brain disease, most often Alzheimer's.
These drugs manage symptoms or slow decline for selected patients. They do not cure dementia. A doctor matches the drug to stage, test results, and side-effect risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which drugs help memory and thinking?
- Which drugs target Alzheimer's plaques?
- What treats agitation in Alzheimer's dementia?
- What risks need close monitoring?
Which drugs help memory and thinking?
Cholinesterase inhibitors are the usual first drugs for cognitive symptoms of mild-to-moderate Alzheimer's dementia. According to the Alzheimer's Association medication guide, donepezil, rivastigmine, and galantamine raise acetylcholine in the brain. Acetylcholine is a chemical messenger that supports attention and memory. Donepezil is approved for all stages of Alzheimer's dementia.
Rivastigmine and galantamine are approved for mild-to-moderate stages. Common side effects include nausea, vomiting, diarrhea, and dizziness. Memantine works a different way for moderate-to-severe Alzheimer's dementia. It regulates glutamate activity as an NMDA antagonist. It is often used with a cholinesterase inhibitor, and the combined memantine-donepezil capsule Namzaric treats the same stage.
Which drugs target Alzheimer's plaques?
Lecanemab and donanemab are amyloid beta-directed antibodies that clear amyloid plaques. They are for early disease with confirmed amyloid in the brain, not for all dementia. Mild cognitive impairment means early memory change that is measurable but does not yet prevent daily tasks.
Lecanemab was FDA-approved in 2023 to slow progression in mild cognitive impairment or mild dementia with confirmed amyloid pathology. Donanemab is given as an intravenous infusion every four weeks, according to the FDA approval notice. It was FDA-approved July 2, 2024 for early symptomatic Alzheimer's disease in amyloid-confirmed patients. Ask the clinic about these practical checks before referral:.
- Is symptoms stage mild cognitive impairment, mild dementia, or early symptomatic disease?
- Is amyloid confirmed by PET scan or spinal-fluid testing?
- Can the patient attend regular infusions and brain scans?
- Are blood thinners, bleeding risk, or prior brain swelling part of the history?
What treats agitation in Alzheimer's dementia?
Brexpiprazole is the drug approved for agitation linked to dementia due to Alzheimer's disease. Agitation includes restlessness, pacing, yelling, threats, or aggression that distresses the patient or others. Non-drug steps such as pain treatment, sleep care, routine, and calmer surroundings usually come first. Brexpiprazole became the first FDA-approved drug for this use on May 11, 2023, according to the FDA press release.
Approval rested on two 12-week placebo-controlled trials in patients ages 51-90. Families should ask what behavior improved, how sleep and alertness changed, and when to review dose. This approval does not make it a general calming drug for other dementias. It is specific to agitation associated with dementia due to Alzheimer's disease. Other psychosis, anxiety, sleep, or depression symptoms need separate review.
What risks need close monitoring?
Anti-amyloid drugs can cause brain swelling and bleeding that require MRI monitoring. Warning signs include headache, dizziness, confusion, vision change, trouble walking, or unusual bleeding. Report new symptoms quickly and keep every scheduled scan. Antipsychotics including brexpiprazole carry a boxed warning of increased death risk in elderly patients with dementia-related psychosis.
A boxed warning is the FDA's strongest safety alert. Use the lowest useful dose, for the shortest useful time, with regular review. Everyday side effects also matter for care plans. Cholinesterase inhibitors often cause nausea, vomiting, diarrhea, and dizziness. Bring a full medication list, fall history, weight change, and driving or cooking safety concerns to the prescribing visit.
You Might Also Like
- What Are the Seven Stages of Dementia Progression?
- Hearing Aids in the 2026 WHO Dementia Guideline: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician
- Air Pollution in the 2026 WHO Dementia Guideline: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician





